Wiley-Blackwell A Special Report on Gene Therapy

This special report provides an up–to–date overview on the gene therapy industry and contains a wealth of practical information on 105 companies. For each company, information is available on the people to contact, their contact details, a corporate history, the company′s technologies and products, financial data, patents held, products in clinical trials, collaborations with other companies and selected publications from the company′s scientists. Almost 200 companies were initially considered for inclusion but just over 100 companies were finally selected as they fulfilled the necessary critieria to be classified as a ′Gene Therapy Company′ defined broadly to include cell therapy companies. As part of this project, new companies were discovered that have not been reported in other publications or on the internet. Dr Jain has spared no effort to ensure that the information is up–to–date and accurate at the time of publishing. In most instances, the information was reviewed by the companies to correct any outdated information or to add any complementary or recent information. In addition to the detailed descriptions of each company, the data is also presented in summary tabular form so that at a glance the reader can identify collaborations within the gene therapy industry, or determine which companies are pursuing strategies involving viral, non–viral, or other approaches to gene therapy, and which diseases are being targetted. Given that much of the gene therapy research and development is currently being carried out within the industrial sector, it is important for scientists, managers, and investors to have the relevant information at their fingertips. This special report provides that information in one accurate, easy to consult and up–to–date source.